Deuterium substituted xanthine derivatives
AssigneeConcert Pharmaceuticals, Inc.
InventorsRoger D. Tung, Julie F. Liu, Scott L. Harbeson
Life of this patent
Estimating the term…
Abstract
This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. In particular, this invention relates to novel substituted xanthine derivatives that are derivatives of a pentoxifylline metabolite. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial. The compounds of the invention are represented by one of the following structural formulas: wherein the values of R1, R2, Y1 and Y2 are described herein.
Claims27
A compound of Formula C:
- or a pharmaceutically acceptable salt thereof, wherein R1 is selected from —CH3 and —CD3;
- R2 is selected from —CH3 and —CD3;
- Y1 is hydrogen, wherein the isotopic enrichment factor for each designated deuterium atom is at least 5000.
A compound of Formula D:
- or a pharmaceutically acceptable salt thereof, wherein R1 —CH3;
- R2 is selected from —CH3 and —CD3;
- Y1 is hydrogen;
- wherein the isotopic enrichment factor for each designated deuterium atom is at least 5000.
A compound of the following formula:
- or a pharmaceutically acceptable salt thereof, wherein the isotopic enrichment factor for each designated deuterium atom is at least 5000.
Dependencies are inferred from the claim text.